These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 30339927)

  • 21. High accuracy of Swedish death certificates in men participating in screening for prostate cancer: a comparative study of official death certificates with a cause of death committee using a standardized algorithm.
    Godtman R; Holmberg E; Stranne J; Hugosson J
    Scand J Urol Nephrol; 2011 Sep; 45(4):226-32. PubMed ID: 21463227
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of neutrosophic cubic hesitant fuzzy exponential aggregation operators with application in environmental protection problems.
    Rehman AU; Gulistan M; Ali M; Al-Shamiri MM; Abdulla S
    Sci Rep; 2023 Mar; 13(1):5262. PubMed ID: 37002236
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prediction of Pathological Stage in Patients with Prostate Cancer: A Neuro-Fuzzy Model.
    Cosma G; Acampora G; Brown D; Rees RC; Khan M; Pockley AG
    PLoS One; 2016; 11(6):e0155856. PubMed ID: 27258119
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An Extension of the Failure Mode and Effect Analysis with Hesitant Fuzzy Sets to Assess the Occupational Hazards in the Construction Industry.
    Heidary Dahooie J; Vanaki AS; Firoozfar HR; Zavadskas EK; Čereška A
    Int J Environ Res Public Health; 2020 Feb; 17(4):. PubMed ID: 32102295
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of PSA and digital rectal examination on the risk of prostate cancer specific mortality in men with a PSA level <2.5 ng/ml.
    Pashtan I; Chen MH; D'Amico AV
    Cancer Epidemiol; 2014 Oct; 38(5):613-8. PubMed ID: 25164550
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bipolar-valued hesitant fuzzy graph and its application.
    Pandey SD; Ranadive AS; Samanta S
    Soc Netw Anal Min; 2022; 12(1):14. PubMed ID: 34873421
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Deriving a ranking from hesitant fuzzy preference relations under group decision making.
    Zhu B; Xu Z; Xu J
    IEEE Trans Cybern; 2014 Aug; 44(8):1328-37. PubMed ID: 24158525
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence-based medical perspectives: the evolving role of PSA for early detection, monitoring of treatment response, and as a surrogate end point of efficacy for interventions in men with different clinical risk states for the prevention and progression of prostate cancer.
    Lieberman R
    Am J Ther; 2004; 11(6):501-6. PubMed ID: 15543092
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimizing patient selection for prostate monotherapy.
    Lee AK; Schultz D; Renshaw AA; Richie JP; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):673-7. PubMed ID: 11172948
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessing individual risk for prostate cancer.
    Nam RK; Toi A; Klotz LH; Trachtenberg J; Jewett MA; Appu S; Loblaw DA; Sugar L; Narod SA; Kattan MW
    J Clin Oncol; 2007 Aug; 25(24):3582-8. PubMed ID: 17704405
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Screening for prostate cancer--how to manage in 2006?
    Lobel B
    Acta Chir Iugosl; 2005; 52(4):19-21. PubMed ID: 16673588
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Staging for prostate cancer: time to incorporate pretreatment prostate-specific antigen and Gleason score?
    Roach M; Weinberg V; Sandler H; Thompson I
    Cancer; 2007 Jan; 109(2):213-20. PubMed ID: 17167758
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improving Clinical Risk Stratification at Diagnosis in Primary Prostate Cancer: A Prognostic Modelling Study.
    Gnanapragasam VJ; Lophatananon A; Wright KA; Muir KR; Gavin A; Greenberg DC
    PLoS Med; 2016 Aug; 13(8):e1002063. PubMed ID: 27483464
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis.
    Pron G
    Ont Health Technol Assess Ser; 2015; 15(10):1-64. PubMed ID: 26366236
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level.
    Leibovici D; Spiess PE; Agarwal PK; Tu SM; Pettaway CA; Hitzhusen K; Millikan RE; Pisters LL
    Cancer; 2007 Jan; 109(2):198-204. PubMed ID: 17171704
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hesitant triangular fuzzy information aggregation operators based on Bonferroni means and their application to multiple attribute decision making.
    Wang C; Li Q; Zhou X; Yang T
    ScientificWorldJournal; 2014; 2014():648516. PubMed ID: 25140338
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A cell kinetics model for prostate cancer and its application to clinical data and individual patients.
    Dimonte G
    J Theor Biol; 2010 May; 264(2):420-42. PubMed ID: 20176031
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Insulin-like growth factor 1, chromogranin A and prostate specific antigen serum levels in prostate cancer patients and controls.
    Marszalek M; Wachter J; Ponholzer A; Leitha T; Rauchenwald M; Madersbacher S
    Eur Urol; 2005 Jul; 48(1):34-9. PubMed ID: 15967249
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multicriteria group decision making by using trapezoidal valued hesitant fuzzy sets.
    Rashid T; Husnine SM
    ScientificWorldJournal; 2014; 2014():304834. PubMed ID: 25133219
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The digital rectal exam, prostate-specific antigen and transrectal echography in the diagnosis of prostatic cancer].
    Martínez de Hurtado J; Chéchile Toniolo G; Villavicencio Mavrich H
    Arch Esp Urol; 1995 Apr; 48(3):247-59. PubMed ID: 7538749
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.